3 research outputs found
Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain
Aim: To describe treatment patterns and outcomes in nontransplant newly diagnosed multiple myeloma (NDMM) patients in Spain. Methods: This retrospective study included two cohorts of NDMM patients diagnosed between 1 January 2012 to 31 December 2013 and 1 April 2016 to 31 March 2017. Results: Among 113 patients, proteasome inhibitor (PI) + alkylator combinations (49%) and PI-based regimens without an alkylator (30%) were the most common first-line (1L) therapies. Use of PI + immunomodulatory drug-based regimens increased between the cohorts; PI-based regimens without an alkylator/immunomodulatory drug decreased. Use of 1L oral regimens was low but increased over time; use of maintenance therapy was low across both periods. Median 1L duration of treatment was 6.9 months. Conclusion: Short 1L duration of treatment and low use of 1L oral regimens and maintenance therapy highlight unmet needs in NDMM. © 2021 The Authors
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell
(DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was
developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety
of switching from intravenous to subcutaneous administration of rituximab
during first-line induction/maintenance for DLBCL or FL, focusing on
ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients
received subcutaneous rituximab plus standard induction chemotherapy for
DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance
monotherapy for FL for 6–12 cycles. The study included 140 patients:
DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced
adverse events, reaching grade ≥3 in 38 6% and were serious in 30 0%.
AARs occurred in 48 6%, mostly (84 9%) at the injection site, with only
2 1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69 6%. After a median follow-up of
33 5 months, median disease-/event-/progression-free and overall survivals
were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a
good quality-of-life perception at induction/maintenance end. Therefore,
switching to subcutaneous rituximab showed no new safety issues and
maintained efficacy with improved satisfaction and quality of life
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell
(DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was
developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety
of switching from intravenous to subcutaneous administration of rituximab
during first-line induction/maintenance for DLBCL or FL, focusing on
ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients
received subcutaneous rituximab plus standard induction chemotherapy for
DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance
monotherapy for FL for 6–12 cycles. The study included 140 patients:
DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced
adverse events, reaching grade ≥3 in 38 6% and were serious in 30 0%.
AARs occurred in 48 6%, mostly (84 9%) at the injection site, with only
2 1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69 6%. After a median follow-up of
33 5 months, median disease-/event-/progression-free and overall survivals
were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a
good quality-of-life perception at induction/maintenance end. Therefore,
switching to subcutaneous rituximab showed no new safety issues and
maintained efficacy with improved satisfaction and quality of life